Pioneers in Neuroscience

U.S. FDA approves ADUHELM™ (aducanumab-avwa) for Alzheimer’s disease

Biogen and Eisai receive FDA accelerated approval for a new therapy targeting amyloid beta plaque.

Update on Tofersen Access Program Part 1
An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
One day at a time: Kamaria's story

When Kamaria's mother, Mary, was diagnosed with early-onset Alzheimer's, it didn't just change Mary's life. It changed the lives of her whole family. September is World Alzheimer’s month, and Biogen stands together with patients, caregivers, healthcare providers and advocates around the world in the fight against this devastating disease.


For Junghae Suh, head of Biogen’s Gene Therapy Accelerator Unit, it’s about working to deliver potentially life-transforming gene therapy medicines to patients.

Biogen updates delivered to your inbox
9/17/21 9:10 AM EDT
CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
View all news
Diversity, Equity and Inclusion

Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us.

Where Science Meets Humanity

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

Follow us on social media